Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

230615-69-7Varenicline Diamine Impurity

● In Stock

Catalogue No.:	VE0012936
CAS No.:	230615-69-7
Mol. Formula:	C13H14F3N3O
Mol. Weight:	285.26 g/mol

Request a quote

Add to RFQ list

Additional information on CAS 230615-69-7

Parent drug

Varenicline

IUPAC Name

2,3,4,5-Tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine-7,8-diamine

Synonyms

N/A

Smiles

O=C(N1CC(C2)C3=CC(N)=C(N)C=C3C2C1)C(F)(F)F

Pharmacopeial Synonyms

N/A

InChI

InChI=1S/C13H14F3N3O/c14-13(15,16)12(20)19-4-6-1-7(5-19)9-3-11(18)10(17)2-8(6)9/h2-3,6-7H,1,4-5,17-18H2

Description

Varenicline Diamine Impurity, CAS 230615-69-7, is the diamine-associated process-related impurity 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1,5-methano-1H-3-benzazepine-7,8-diamine. With molecular formula C13H14F3N3O and molecular weight 285.26 g/mol, it reflects incomplete conversion or side-reaction pathways during varenicline synthesis, particularly around amination and trifluoroacetyl introduction. The structure contains a rigid azabicyclic benzazepine core bearing adjacent aromatic diamines, which may alter chromatographic behavior and ionization response. Trace-level assessment typically relies on LC-MS/MS, LC-UV with orthogonal confirmation, and, where needed, high-resolution MS for impurity profiling under ICH M7-relevant evaluation.